PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 33257454-2 2021 The standard dosing regimen of cefiderocol is 2 g administered every 8 hours over 3 hours infusion in patients with creatinine clearance (CrCL) of 60 to 119 mL/min, and it is adjusted for patients with < 60 mL/min or >= 120 mL/min CrCL. cefiderocol 31-42 CRCL Homo sapiens 138-142 33257454-2 2021 The standard dosing regimen of cefiderocol is 2 g administered every 8 hours over 3 hours infusion in patients with creatinine clearance (CrCL) of 60 to 119 mL/min, and it is adjusted for patients with < 60 mL/min or >= 120 mL/min CrCL. cefiderocol 31-42 CRCL Homo sapiens 231-235 33256752-1 2020 BACKGROUND: Cefiderocol, ceftazidime-avibactam, ceftolozane-tazobactam, intravenous fosfomycin and plazomicin represent potential carbapenem sparing agents for extended-spectrum-beta-lactamase or AmpC beta-lactamase producing Escherichia coli infection. cefiderocol 12-23 beta-lactamase Escherichia coli 196-200 33058794-0 2021 Cefiderocol: the Trojan horse has arrived but will Troy fall? cefiderocol 0-11 TNF receptor superfamily member 19 Homo sapiens 51-55 32277821-11 2020 All KPC-3-producing K. pneumoniae were susceptible to cefiderocol, even those resistant to ceftazidime/avibactam. cefiderocol 54-65 KPC-3 Klebsiella pneumoniae 4-9 33140656-2 2020 Cefiderocol, a novel siderophore cephalosporin showing in vitro activity against MBL-GNB, has been recently marketed, and a combination of aztreonam and ceftazidime/avibactam has shown a possible favorable effect on survival of patients with severe MBL-GNB infections in observational studies. cefiderocol 0-11 mannose-binding lectin family member 3, pseudogene Homo sapiens 81-84 31724049-4 2019 The improved structure, the novel mode of entry into bacteria, and its stability against carbapenemases enables cefiderocol to exhibit high potency against isolates that produce carbapenemases of all classes or are resistant due to porin channel mutations and/or efflux pump overexpression. cefiderocol 112-123 voltage dependent anion channel 1 Homo sapiens 232-237 31262762-3 2019 The study with multiple carbapenem-resistant strains revealed that the %fT >MIC determined in iron-depleted cation-adjusted Mueller-Hinton broth (ID-CAMHB) better reflected the in vivo efficacy of cefiderocol than the %fT >MIC determined in cation-adjusted Mueller-Hinton broth (CAMHB). cefiderocol 200-211 microphthalmia Japan Mus musculus 79-82 31262762-3 2019 The study with multiple carbapenem-resistant strains revealed that the %fT >MIC determined in iron-depleted cation-adjusted Mueller-Hinton broth (ID-CAMHB) better reflected the in vivo efficacy of cefiderocol than the %fT >MIC determined in cation-adjusted Mueller-Hinton broth (CAMHB). cefiderocol 200-211 microphthalmia Japan Mus musculus 229-232 31262762-4 2019 The mean %fT >MIC of cefiderocol required for a 1-log10 reduction against 10 strains of Enterobacteriaceae and 3 strains of Pseudomonas aeruginosa in the thigh infection models were 73.3% and 77.2%, respectively. cefiderocol 24-35 microphthalmia Japan Mus musculus 17-20 31262762-6 2019 These results indicate that cefiderocol has potent efficacy against Gram-negative bacilli, including carbapenem-resistant strains, irrespective of the bacterial species, in neutropenic thigh and lung infection models and that the in vivo efficacy correlated with the in vitro MIC under iron-deficient conditions. cefiderocol 28-39 microphthalmia Japan Mus musculus 276-279 29627897-2 2018 In vitro studies demonstrated inhibition potential of cefiderocol on organic anion transporter (OAT) 1, OAT3, organic cation transporter (OCT) 1, OCT2, multidrug and toxin extrusion (MATE) 2-K, and organic anion transporting polypeptide (OATP) 1B3. cefiderocol 54-65 solute carrier family 22 member 6 Homo sapiens 69-102 29627897-2 2018 In vitro studies demonstrated inhibition potential of cefiderocol on organic anion transporter (OAT) 1, OAT3, organic cation transporter (OCT) 1, OCT2, multidrug and toxin extrusion (MATE) 2-K, and organic anion transporting polypeptide (OATP) 1B3. cefiderocol 54-65 solute carrier family 22 member 8 Homo sapiens 104-108 29627897-2 2018 In vitro studies demonstrated inhibition potential of cefiderocol on organic anion transporter (OAT) 1, OAT3, organic cation transporter (OCT) 1, OCT2, multidrug and toxin extrusion (MATE) 2-K, and organic anion transporting polypeptide (OATP) 1B3. cefiderocol 54-65 solute carrier family 22 member 1 Homo sapiens 110-144 29627897-2 2018 In vitro studies demonstrated inhibition potential of cefiderocol on organic anion transporter (OAT) 1, OAT3, organic cation transporter (OCT) 1, OCT2, multidrug and toxin extrusion (MATE) 2-K, and organic anion transporting polypeptide (OATP) 1B3. cefiderocol 54-65 POU class 2 homeobox 2 Homo sapiens 146-150 29627897-2 2018 In vitro studies demonstrated inhibition potential of cefiderocol on organic anion transporter (OAT) 1, OAT3, organic cation transporter (OCT) 1, OCT2, multidrug and toxin extrusion (MATE) 2-K, and organic anion transporting polypeptide (OATP) 1B3. cefiderocol 54-65 solute carrier organic anion transporter family member 1B3 Homo sapiens 198-247 35594628-1 2022 INTRODUCTION: Cefiderocol is a siderophore cephalosporin antibiotic and first of its kind approved by the Food and Drug Administration for the treatment of complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years or older caused by susceptible organisms. cefiderocol 14-25 hyaluronan binding protein 2 Homo sapiens 269-273 35594628-1 2022 INTRODUCTION: Cefiderocol is a siderophore cephalosporin antibiotic and first of its kind approved by the Food and Drug Administration for the treatment of complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years or older caused by susceptible organisms. cefiderocol 14-25 potassium voltage-gated channel interacting protein 1 Homo sapiens 274-278 35625225-3 2022 Human umbilical vein cells (HUVECs), co-cultured with erythrocyte-depleted whole blood for up to 48 h, were activated with tumor necrosis factor-alpha (TNF-alpha) or lipopolysaccharide (LPS) to induce endothelial damage in the absence or presence of cefiderocol (concentrations of 10, 40 and 70 mg/L). cefiderocol 250-261 tumor necrosis factor Homo sapiens 123-150 35625225-3 2022 Human umbilical vein cells (HUVECs), co-cultured with erythrocyte-depleted whole blood for up to 48 h, were activated with tumor necrosis factor-alpha (TNF-alpha) or lipopolysaccharide (LPS) to induce endothelial damage in the absence or presence of cefiderocol (concentrations of 10, 40 and 70 mg/L). cefiderocol 250-261 tumor necrosis factor Homo sapiens 152-161 35625225-6 2022 Furthermore, cefiderocol reduces interleukin-6 (IL-6), interleukin-1beta (IL-1beta) and TNF-alpha release in peripheral blood mononuclear cells (PBMCs) following LPS stimulation in a dose-dependent manner. cefiderocol 13-24 interleukin 6 Homo sapiens 33-46 35625225-6 2022 Furthermore, cefiderocol reduces interleukin-6 (IL-6), interleukin-1beta (IL-1beta) and TNF-alpha release in peripheral blood mononuclear cells (PBMCs) following LPS stimulation in a dose-dependent manner. cefiderocol 13-24 interleukin 6 Homo sapiens 48-52 35625225-6 2022 Furthermore, cefiderocol reduces interleukin-6 (IL-6), interleukin-1beta (IL-1beta) and TNF-alpha release in peripheral blood mononuclear cells (PBMCs) following LPS stimulation in a dose-dependent manner. cefiderocol 13-24 interleukin 1 beta Homo sapiens 55-72 35625225-6 2022 Furthermore, cefiderocol reduces interleukin-6 (IL-6), interleukin-1beta (IL-1beta) and TNF-alpha release in peripheral blood mononuclear cells (PBMCs) following LPS stimulation in a dose-dependent manner. cefiderocol 13-24 interleukin 1 alpha Homo sapiens 74-82 35625225-6 2022 Furthermore, cefiderocol reduces interleukin-6 (IL-6), interleukin-1beta (IL-1beta) and TNF-alpha release in peripheral blood mononuclear cells (PBMCs) following LPS stimulation in a dose-dependent manner. cefiderocol 13-24 tumor necrosis factor Homo sapiens 88-97